Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.
प्रकार | दैनिक | साप्ताहिक | मासिक |
|---|---|---|---|
| मूविंग एवरेज | मजबूत विक्रय | मजबूत विक्रय | मजबूत विक्रय |
| तकनीकी संकेतक | मजबूत विक्रय | मजबूत विक्रय | मजबूत विक्रय |
| सारांश | मजबूत विक्रय | मजबूत विक्रय | मजबूत विक्रय |
नाम | अंतिम | उच्च | निम्न | बदलाव | बदलाव % | वॉल्यूम | समय | ||
|---|---|---|---|---|---|---|---|---|---|
| 375.00 | 384.00 | 361.35 | +0.05 | +0.01% | 42.15K | BSE | |||
| 3.74 | 3.80 | 3.65 | +0.010 | +0.27% | 298.40K | BSE | |||
| 1,141.95 | 1,152.00 | 1,097.85 | +43.30 | +3.94% | 7.28K | BSE | |||
| 3.30 | 3.50 | 3.20 | -0.05 | -1.49% | 3.40M | NSE | |||
| 10.84 | 11.92 | 10.80 | -0.52 | -4.58% | 908.29K | BSE | |||
| 131.00 | 134.15 | 129.70 | +1.85 | +1.43% | 6.79K | NSE | |||
| 1.56 | 1.64 | 1.50 | -0.01 | -0.64% | 85.18K | BSE | |||
| 141.50 | 141.50 | 134.10 | +6.55 | +4.85% | 2.38K | NSE | |||
| 69.00 | 73.70 | 68.30 | -3.35 | -4.63% | 20.88K | NSE | |||
| 0.05 | 0.05 | 0.05 | 0.00 | 0.00% | 0.00 | NSE | |||
| 921.05 | 932.00 | 920.00 | -8.15 | -0.88% | 108.51K | NSE | |||
| 935.50 | 1,003.90 | 887.55 | +33.00 | +3.66% | 8.47K | NSE | |||
| 130.70 | 132.30 | 130.30 | 0.00 | 0.00% | 0.00 | NSE | |||
| 2,679.40 | 2,719.95 | 2,605.40 | +51.25 | +1.95% | 11.10K | NSE | |||
| 1.60 | 1.65 | 1.50 | +0.10 | +6.67% | 2.61M | NSE |